What is the recommended dose and dosing frequency of Monoferric (ferric derisomaltose) for treating iron deficiency anemia in adults?

Monoferric Dosing for Iron Deficiency Anemia

For adults weighing ≥50 kg, administer 1000 mg of Monoferric as a single intravenous infusion over at least 20 minutes; for those <50 kg, give 20 mg/kg (maximum 1500 mg) as a single dose. 1

Weight-Based Dosing

• Patients ≥50 kg: 1000 mg IV as a single infusion 1
• Patients <50 kg: 20 mg/kg actual body weight IV as a single infusion, not exceeding 1500 mg 1
• Monoferric is the only FDA-approved IV iron formulation labeled for total-dose infusion, allowing complete iron repletion in one administration 2, 3

Preparation and Administration

• Dilute the appropriate dose in 100–500 mL of 0.9% sodium chloride (final concentration >1 mg iron/mL) 1
• Infuse over at least 20 minutes (some guidelines recommend 30 minutes for the full 1000 mg dose) 2, 3, 1
• The diluted solution is stable at room temperature for up to 8 hours 1
• Do not mix Monoferric with other drugs in the same infusion 1
• Monitor for extravasation; if it occurs, discontinue the infusion immediately, as brown discoloration at the site may be long-lasting 1

Frequency of Repeat Dosing

Reassess laboratory parameters 4–8 weeks after the initial infusion to determine whether additional iron is needed; do not use a fixed weekly schedule. 3

• Single infusion is sufficient when the underlying cause of iron deficiency has been corrected (e.g., after treatment of bleeding source) 2, 3
• Repeat dosing is required in the presence of ongoing iron loss or malabsorption: 2, 3
  • Heavy menstrual bleeding
  • Gastrointestinal bleeding (angiodysplasia, hereditary hemorrhagic telangiectasia)
  • Inflammatory bowel disease
  • Malabsorption (post-bariatric surgery, celiac disease, autoimmune gastritis)
• The interval between repeat doses should be guided by the magnitude of ongoing loss or malabsorption, not a predetermined schedule 2, 3

Post-Infusion Monitoring

Draw labs 4–8 weeks after the infusion; avoid testing within the first 4 weeks because circulating iron interferes with assays. 2, 3

At the 4–8 week visit, assess: 2, 3

• Complete blood count (CBC): Hemoglobin should rise 1–2 g/dL within 4–8 weeks 2, 3
• Serum ferritin: Target ≥50 ng/mL in the absence of inflammation 2, 3
• Transferrin saturation (TSAT): A value <20% indicates persistent iron deficiency 2, 3

Safety Precautions

• Hypersensitivity monitoring: Observe patients for at least 30 minutes after completion of the infusion and until clinically stable 1
• Only administer when personnel and therapies for treating serious hypersensitivity reactions are immediately available 1
• Serious or severe hypersensitivity reactions occurred in 0.3% of patients in clinical trials 1
• Monoferric is contraindicated in patients with prior serious hypersensitivity to the product 1

Comparative Advantages Over Other IV Iron Formulations

• Single-dose convenience: Unlike ferric carboxymaltose (which requires two 750 mg doses one week apart in the US) or iron sucrose (which requires 5–11 separate 200 mg infusions), Monoferric achieves full repletion in one visit 2, 4, 3
• Lower hypophosphatemia risk: Monoferric causes hypophosphatemia in approximately 4% of patients, compared to 58% with ferric carboxymaltose and 1% with iron sucrose 4
• Cardiovascular outcomes: In heart failure patients with iron deficiency, Monoferric was the first IV iron formulation to demonstrate a statistically significant reduction in cardiovascular mortality 2, 3, 5

Clinical Efficacy Data

• In real-world postpartum hemorrhage studies, single-dose Monoferric (1000 mg) achieved significantly higher hemoglobin levels and lower anemia rates at 2 weeks and 1 month compared to conventional IV plus oral iron therapy 6
• In patients with chronic kidney disease, a single Monoferric infusion produced faster hematological response and fewer cardiovascular adverse events compared to multiple iron sucrose doses 7
• In menorrhagia-associated anemia, 92.8% of Monoferric patients achieved their cumulative iron dose within 8 weeks, versus only 43.2% with iron sucrose 8

Common Pitfalls to Avoid

• Do not draw iron studies within 4 weeks of the infusion; circulating iron causes spurious laboratory results 2, 3
• Do not use a fixed weekly dosing schedule for repeat infusions; base the interval on clinical reassessment at 4–8 weeks 3
• Do not administer to patients with iron overload (elevated ferritin in the absence of inflammation); excessive iron can lead to hemosiderosis 1
• Monitor for extravasation during infusion; brown discoloration can be permanent 1